Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis.
Hochmair MJ, Fabikan H, Illini O, Weinlinger C, Setinek U, Krenbek D, Prosch H, Rauter M, Schumacher M, Wöll E, Wass R, Brehm E, Absenger G, Bundalo T, Errhalt P, Urban M, Valipour A.
Hochmair MJ, et al.
Pharmaceuticals (Basel). 2020 Nov 7;13(11):371. doi: 10.3390/ph13110371.
Pharmaceuticals (Basel). 2020.
PMID: 33171712
Free PMC article.